Skip to content

Tango Therapeutics TNGX Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin-178.4%+168pp-346.1%-33.5pp-312.6%+134pp-446.8%-290pp
Net margin-162.9%+147pp-309.7%-31.2pp-278.5%+157pp-435.1%-278pp
EBITDA margin-174.7%+165pp-340.1%-34.2pp-306%+134pp-440.3%-328pp
Free cash flow margin-224.3%+90.1pp-314.4%+12.8pp-327.2%+143pp-469.7%-304pp
Returns
Return on equity-37.2%+20.3pp-57.6%-17.1pp-40.5%-4.1pp-36.4%-6.0pp
Return on assets-28.4%+7.8pp-36.2%-12.0pp-24.3%-1.2pp-23.1%-6.6pp
Return on invested capital-51.3%+23.4pp-74.7%-24.4pp-50.3%+0.9pp-51.2%-16.9pp
Efficiency
Asset turnover0.2×+0.1×0.1×0.0×0.1×0.0×0.1×-0.1×
Liquidity
Current ratio16.3×+9.3×-0.6×7.5×+0.8×6.8×-5.3×
Quick ratio16.3×+9.3×-0.6×7.5×+0.8×6.8×-5.3×
Cash ratio5.2×+3.4×1.8×+0.4×1.4×+0.4×1.1×-2.4×
Leverage
Debt-to-equity0.1×-0.1×0.2×0.0×0.1×0.0×0.2×+0.2×
Debt-to-assets0.1×0.0×0.1×0.0×0.1×0.0×0.1×+0.1×
Per Share
Book value per share$2.98+63.1%$1.83-31.7%$2.68-5.8%$2.84-48.8%
Valuation
Market capitalization$1.19B+259%$331.92M-65.5%$962.51M+50.9%$637.79M-33.5%
Enterprise value$1.11B+273%$298.88M-68.0%$932.62M+50.7%$618.96M-24.3%
Price / sales19.1×+11.2×7.9×-18.5×26.4×+0.7×25.7×-0.2×
Price / book3.4×+1.8×1.7×-2.1×3.8×+1.2×2.6×-0.2×
EV / sales17.9×+10.8×7.1×-18.4×25.5×+0.6×24.9×+2.8×
Free cash flow yield-11.7%+28.1pp-39.8%-27.4pp-12.4%+5.9pp-18.3%-11.9pp
Earnings yield-8.5%+30.7pp-39.3%-28.7pp-10.6%+6.4pp-17%-10.9pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Tango Therapeutics's ratios come from?
Every ratio is computed from Tango Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.